Kurzfassung

Asteria II A Phase III., multicenter, randomized, double-blind, dose-ranging, placebo-contolled study to evaluate the efficacy, response duration and safety of XOLAIR (Omalizumab)in patients with chronic idiopathic urticaria (CIU) who remain symptomatic despite antihistamine treatment (H1)